Voyager Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics Announces Pricing of Public Offering
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
Novartis will launch another gene therapy satellite with Voyager Therapeutics in a $100 million upfront deal to develop candidates in Huntington’s disease and spinal muscular atrophy.
Pfizer has handed off an AAV capsid aimed at a rare neurological disease target to AstraZeneca’s rare disease arm Alexion as part of a larger, previously announced bundle deal.
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics is tripling down on its Alzheimer’s disease franchise, this time with a gene therapy aimed at amyloid-beta plaques.
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Price Prediction: Will VGX Thrive Despite Crypto Lender’s Bankruptcy, SEC Claims?